参考文献/References:
[1] Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J].Nature, 2012, 481(7382): 463-468.
[2] Spiegelman BM. Banting Lecture 2012: Regulation of adipogenesis: toward new therapeutics for metabolic disease[J].Diabetes, 2013, 62(6): 1774-1782.
[3] Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine[J].PLoS One, 2013, 8(4): e60563.
[4] Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans[J].PLoS One, 2013, 8(9): e73680.
[5] Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Maternal inheritance of circulating irisin in humans[J].Clin Sci(Lond), 2014, 126(12): 837-844.
[6] Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise[J].Metabolism, 2012, 61(12): 1725-1738.
[7] Hofmann T, Elbelt U, Stengel A. irisin as a muscle-derived hormone stimulating thermogenesis-A critical update[J].Peptides, 2014, 54C: 89-100.
[8] Schumacher MA, Chinnam N, Ohashi T, et al. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type Ⅲ(FNIII)dimer: implications for receptor activation[J].J Biol Chem, 2013, 288(47): 33738-33744.
[9] Lee P, Linderman JD, Smith S, et al. irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans[J].Cell Metab, 2014, 19(2): 302-309.
[10] Aydin S, Aydin S, Kuloglu T, et al. Alterations of irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45 min of a Turkish bath or running[J].Peptides, 2013, 50: 13-18.
[11] Vaughan RA, Garcia-Smith R, Bisoffi M, et al. Conjugated linoleic acid or omega 3 fatty acids increase mitochondrial biosynthesis and metabolism in skeletal muscle cells[J].Lipids Health Dis, 2012, 11: 142.
[12] Huh JY, Dincer F, Mesfum E, et al. irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J].Int J Obes(Lond), 2014,[Epub ahead of print].
[13] Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans[J].Am J Physiol Endocrinol Metab, 2007, 293(2): E444-E452.
[14] van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men[J].N Engl J Med, 2009, 360(15): 1500-1508.
[15] Zhang Y, Li R, Meng Y, et al. irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling[J].Diabetes, 2014, 63(2): 514-525.
[16] Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway[J].Cell Metab, 2013, 18(5): 649-659.
[17] Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes[J].J Clin Invest, 2012, 122(3): 1022-1036.
[18] Lee P, Werner CD, Kebebew E, Celi FS. Functional thermogenic beige adipogenesis is inducible in human neck fat[J].Int J Obes(Lond), 2014, 38(2): 170-176.
[19] Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice[J].Diabetologia, 2012, 55(1): 183-193.
[20] Shan T, Liang X, Bi P, et al. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle[J].FASEB J, 2013, 27(5): 1981-1989.
[21] Crujeiras AB, Pardo M, Arturo RR, et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women[J].Am J Hum Biol, 2014, 26(2): 198-207.
[22] Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index[J].Peptides, 2013, 39: 125-130.
[23] Sesti G, Andreozzi F, Fiorentino TV, et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects[J].Acta Diabetol, 2014,[Epub ahead of print].
[24] Hee Park K, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome[J].J Clin Endocrinol Metab, 2013, 98(12): 4899-4907.
[25] Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, et al. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects[J].Nutr Diabetes, 2014, 4: e110.
[26] Piya MK, Harte AL, Sivakumar K, et al. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes[J].Am J Physiol Endocrinol Metab, 2014, 306(5): E512-E518.
[27] Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies[J].J Physiol, 2014, 592(Pt 5): 1091-1107.
[28] Zhang HJ, Zhang XF, Ma ZM, et al. irisin is inversely associated with intrahepatic triglyceride contents in obese adults[J].J Hepatol, 2013, 59(3): 557-562.
[29] Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese chinese adults[J].PLoS One, 2014, 9(4): e94235.
[30] Blüher S, Panagiotou G, Petroff D, et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children[J].Obesity(Silver Spring), 2014, 22(7): 1701-1708.
[31] Roberts MD, Bayless DS, Company JM, et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats[J].Metabolism,2013,62(8): 1052-1056.
[32] Moreno-Navarrete JM, Ortega F, Serrano M, et al. irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance[J].J Clin Endocrinol Metab, 2013, 98(4): E769-E778.
[33] Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes[J].Diabetes Res Clin Pract, 2013, 100(1): 96-101.
[34] Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus[J].J Diabetes Complications, 2013, 27(4): 365-369.
[35] Liu JJ, Liu S, Wong MD, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes[J].J Diabetes Complications, 2014, 28(2): 208-213.
[36] Staiger H, B hm A, Scheler M, et al. Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived'browning' factor irisin, determines insulin sensitivity[J].PLoS One, 2013, 8(4): e61903.
[37] Ebert T, Stepan H, Schrey S, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery[J].Cytokine, 2014, 65(2): 153-158.
[38] Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus[J].Diabetes Res Clin Pract, 2014, 104(1): 171-175.
[39] Polyzos SA, Kountouras J, Anastasilakis AD, et al. irisin in patients with nonalcoholic fatty liver disease[J].Metabolism, 2014, 63(2): 207-217.
[40] de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, et al. Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients[J].Clin Endocrinol(Oxf), 2013, [Epub ahead of print].
[41] Gouni-Berthold I, Berthold HK, Huh JY, et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo[J].PLoS One, 2013, 8(9): e72858.
[42] Anastasilakis AD, Polyzos SA, Makras P, et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months[J].Osteoporos Int, 2014, 25(5): 1633-1642.
相似文献/References:
[1]刘璐,李鸿.代谢调控的新靶点——Irisin[J].国际内分泌代谢杂志,2014,(02):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
Liu Lu,Li Hong..A new target in metabolic control--Irisin[J].International Journal of Endocrinology and Metabolism,2014,(05):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
[2]谢绍锋,黄莉吉,王昆,等.南京市城区40岁以上人群超重、肥胖流行
特点调查分析[J].国际内分泌代谢杂志,2016,36(03):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
Xie Shaofeng*,Huang Liji,Wang Kun,et al.Epidemiological investigation of overweight and obesity in population aged 40 years or older in Nanjing City[J].International Journal of Endocrinology and Metabolism,2016,36(05):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
[3]祝凌妃,杨震,秦利.肌肉因子与代谢性疾病[J].国际内分泌代谢杂志,2016,36(05):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
Zhu Lingfei,Yang Zhen,Qin li.Myokines and metabolic disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
[4]项芬芬,张学梅,高英慧,等.p53与物质能量代谢的关系[J].国际内分泌代谢杂志,2017,37(04):262.
Xiang Fenfen*,Zhang Xuemei,Gao Yinghui,et al.Relationship between p53 and material, energy metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(05):262.
[5]杨雪 相萍萍 陈国芳 刘超.IGF-1在代谢性疾病中的作用[J].国际内分泌代谢杂志,2018,38(01):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
Yang Xue,Xiang Pingping,Chen Guofang,et al.Effects of IGF-1 in metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(05):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
[6]杨雪 韦晓 杨婉薇 陈国芳 刘超.代谢组学在糖尿病研究中的应用[J].国际内分泌代谢杂志,2018,38(05):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
Yang Xue,Wei Xiao,Yang Wanwei,et al.Application of metabonomics in diabetic research[J].International Journal of Endocrinology and Metabolism,2018,38(05):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
[7]王佳蓓 陈风 刘莹 王涤非.Nur77与物质能量代谢的关系[J].国际内分泌代谢杂志,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
Wang Jiabei,Chen Feng,Liu Ying,et al.Relationship between Nur77 and meterial, energy metabolism[J].International Journal of Endocrinology and Metabolism,2019,39(05):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
[8]王雪 朱惠娟 龚凤英.棕色脂肪因子与代谢性疾病[J].国际内分泌代谢杂志,2019,39(06):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
Wang Xue,Zhu Huijuan,Gong Fengying.Relationship between brown adipocytokine and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2019,39(05):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
[9]王鹏程,姜长涛.肠源神经酰胺与代谢性疾病[J].国际内分泌代谢杂志,2021,41(04):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
Wang Pengcheng,Jiang Changtao..Relationship between intestinal ceramide and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2021,41(05):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
[10]乔晶,刘乙君,王彦.甘油三酯-葡萄糖指数与胰岛素抵抗相关代谢性疾病的关系[J].国际内分泌代谢杂志,2022,42(03):223.[doi:10.3760/cma.j.cn121383-20210206-02013]
QiaoJing,LiuYijun,WangYan..Relationship between triglyceride-glucose index and insulin resistance-related metabolic diseases[J].International Journal of Endocrinology and Metabolism,2022,42(05):223.[doi:10.3760/cma.j.cn121383-20210206-02013]
[11]陈恺情,卜瑞芳.Irisin——可否让代谢性疾病治疗进入新时代[J].国际内分泌代谢杂志,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
Chen Kaiqing,Bu Ruifang..Could irisin lead the treatment of metabolic diseases into a new era?[J].International Journal of Endocrinology and Metabolism,2016,36(05):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]